Teva and Sanofi’s IBD Drug Achieves Primary Targets in Phase 2 Study

/in /tarafından

Israel’s Teva Pharmaceutical Industries and French drugmaker Sanofi announced that their jointly developed drug for treating ulcerative colitis and Crohn’s disease has successfully met its primary goals in a Phase 2b clinical trial.

The drug, named duvakitug, demonstrated strong efficacy across patient subgroups. In the 14-week trial, 36.2% of patients receiving the low dose and 47.8% receiving the high dose achieved clinical remission, compared to 20.45% of those on a placebo. The study, conducted across the U.S., Europe, and Israel, marks the first randomized, placebo-controlled trial to assess a TL1A antibody treatment for Crohn’s disease.

Promising Results and Market Potential

Eric Hughes, Teva’s head of global R&D, said, “The results from the study have exceeded our expectations.” Similarly, Houman Ashrafian, Sanofi’s head of R&D, highlighted duvakitug’s potential as a transformative treatment: “If the magnitude of effect persists in the Phase 3 program, we believe we will have a differentiated medicine for IBD patients who are in urgent need of new options.”

The drug was generally well-tolerated, with no safety signals identified in patients with both ulcerative colitis and Crohn’s disease. Full results of the study will be presented at a scientific forum in 2025.

Next Steps: Phase 3 Development

Teva and Sanofi plan to move forward with Phase 3 development of duvakitug, pending discussions with regulatory authorities. Both companies noted that inflammatory bowel disease (IBD) currently has no cure, underscoring the urgent need for innovative treatments.

Under the partnership agreement, Teva received a $500 million upfront payment from Sanofi and stands to earn up to $1 billion in development and launch milestones. The companies will equally share development costs and split net profits and losses in major markets.

Commercialization Strategy

Sanofi will take the lead on commercialization in North America, Japan, Asia, and other global regions, while Teva will oversee the European, Israeli, and selected markets.

Market Reaction and Investor Sentiment

Following the announcement, U.S.-listed shares of Teva surged 19%, while Sanofi’s shares climbed 4% in early trading. Analysts, including Jefferies’ Glen Santangelo, said the positive trial results will ease investor concerns that had weighed on Teva’s shares after its third-quarter performance.

Both companies remain optimistic that duvakitug could become a blockbuster drug, generating annual sales exceeding $1 billion, and offering new hope to millions of patients suffering from ulcerative colitis and Crohn’s disease worldwide.

 

Pfizer Sees Stable Vaccine Policy Under Trump Despite RFK Jr. Appointment

/in /tarafından

Pfizer does not anticipate major changes to U.S. vaccine policies under the Trump administration in 2025, even though President-elect Donald Trump has nominated Robert F. Kennedy Jr., a vaccine skeptic, to head the Department of Health and Human Services (HHS).

Speaking at an investor conference, Pfizer CEO Albert Bourla confirmed he had met with both Trump and RFK Jr. over dinner and described their relationship as positive. “If he’s confirmed, we will work with him to advance the right policies,” Bourla said.

Kennedy has long been criticized for questioning the safety and efficacy of vaccines, which have been instrumental in combating disease worldwide. While he rejects the “anti-vaccine” label, Kennedy has indicated that he would not block access to vaccines. Trump, meanwhile, has suggested that he may end certain childhood vaccination programs if concerns about safety arise.

Bourla highlighted Trump’s commitment to reforming the role of pharmacy benefit managers (PBMs), middlemen in the U.S. healthcare system who negotiate drug prices. Trump announced plans to eliminate PBMs, which Bourla argued could significantly lower patient out-of-pocket costs for medications.

Vaccine Market Outlook

Pfizer, which produces vaccines for COVID-19, pneumococcal disease, and RSV (respiratory syncytial virus), has faced market pressure since Trump’s announcement of Kennedy as his HHS nominee. However, Bourla reassured investors that Pfizer expects 2025 sales for its COVID-19 vaccine and treatment to remain consistent with 2024 levels.

Financial Performance and Turnaround Strategy

Pfizer’s financial outlook provided some relief to investors amid ongoing concerns over its future performance. The company forecasts 2025 adjusted profit between $2.80 and $3.00 per share, in line with analysts’ average estimate of $2.88. It also projects revenue between $61 billion and $64 billion, slightly below Wall Street’s consensus of $63.26 billion.

Shares rose 3.7% to $26.20 following the forecast, though Pfizer’s stock has dropped nearly 12% this year and remains well below its pandemic-era peak. The pharmaceutical giant has faced investor criticism, most notably from hedge fund Starboard Value, over its acquisition strategy and the lack of profitable drugs resulting from recent deals and internal research efforts.

In response, Bourla defended Pfizer’s strategy, which includes aggressive cost-cutting measures and the sale of non-core businesses to reduce debt. The company is under increasing pressure to introduce new blockbuster drugs to offset revenue declines from top sellers set to lose patent protection.

Conclusion

Despite concerns surrounding Trump’s choice of RFK Jr. for HHS and broader investor criticism, Pfizer remains cautiously optimistic about vaccine policies and its financial performance in 2025. The company continues to focus on cost efficiency, innovation, and policy collaboration to stabilize its outlook in a challenging post-pandemic environment.

 

Scientists Suggest Decline in Planetary Albedo May Contribute to Sharp Increase in Global Temperatures

/in /tarafından

Researchers from the Alfred Wegener Institute (AWI) have uncovered a potential link between a sharp decline in the Earth’s planetary albedo and the unprecedented rise in global temperatures in 2023. The study suggests that the reduction in low-altitude clouds is contributing to this alarming trend, which has pushed the global mean temperature nearly 1.5°C above pre-industrial levels. Dr. Helge Goessling, a climate modeller at AWI and lead author of the study, highlighted that this phenomenon could explain an additional 0.2°C of warming that current climate models, including factors like greenhouse gases, El Niño, and volcanic activity, fail to account for.

The research, published in Science, draws attention to the significant loss of low-altitude cloud cover, especially in the northern mid-latitudes and tropics. These clouds, which are typically reflective, play a crucial role in maintaining Earth’s energy balance by reflecting sunlight back into space. The data from NASA and the European Centre for Medium-Range Weather Forecasts (ECMWF) show that 2023 experienced the lowest planetary albedo since at least 1940, marking a notable shift in the planet’s reflectivity. With less sunlight being reflected, more heat is absorbed, which accelerates global warming.

The reduction in low-altitude clouds, which provide a natural cooling effect, contrasts with higher clouds that tend to trap heat, further exacerbating the warming process. The study suggests several factors may be contributing to this change, including stricter marine fuel regulations, which have reduced aerosol concentrations needed for cloud formation, and shifts in oceanic conditions. However, Dr. Goessling proposed that there could be a significant feedback loop at play, where global warming leads to further reduction in cloud cover, which, in turn, enhances warming—a vicious cycle that could escalate the effects of climate change.

These findings underscore the complexity of climate change and the need for more comprehensive models that account for all contributing factors. While greenhouse gas emissions and natural climate phenomena like El Niño remain key drivers of global warming, the reduction in planetary albedo due to changing cloud patterns presents an important piece of the puzzle. Researchers are calling for further investigation into how these feedback loops may accelerate the pace of global warming and what measures can be taken to mitigate their effects.